234 related articles for article (PubMed ID: 16280257)
1. Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders.
Baron F; Storb R
Mol Ther; 2006 Jan; 13(1):26-41. PubMed ID: 16280257
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning.
Baron F; Sandmaier BM
Leukemia; 2006 Oct; 20(10):1690-700. PubMed ID: 16871276
[TBL] [Abstract][Full Text] [Related]
4. Treatment of hematological malignancies with allogeneic nonmyeloablative stem cell transplantation: conditioning regimens with fludarabine.
Carella AM
Hematol J; 2004; 5 Suppl 1():S68-75. PubMed ID: 15079155
[TBL] [Abstract][Full Text] [Related]
5. Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation.
Georges GE; Storb R
Int J Hematol; 2003 Jan; 77(1):3-14. PubMed ID: 12568294
[TBL] [Abstract][Full Text] [Related]
6. Current roles for allogeneic hematopoietic cell transplantation following nonmyeloablative or reduced-intensity conditioning.
Baron F; Storb R
Clin Adv Hematol Oncol; 2005 Oct; 3(10):799-819. PubMed ID: 16258490
[TBL] [Abstract][Full Text] [Related]
7. Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives.
Sandmaier BM; Mackinnon S; Childs RW
Biol Blood Marrow Transplant; 2007 Jan; 13(1 Suppl 1):87-97. PubMed ID: 17222778
[TBL] [Abstract][Full Text] [Related]
8. Nonmyeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation: a clinical review.
Pollack SM; O'Connor TP; Hashash J; Tabbara IA
Am J Clin Oncol; 2009 Dec; 32(6):618-28. PubMed ID: 19593085
[TBL] [Abstract][Full Text] [Related]
9. Nonmyeloablative allogeneic hematopoietic cell transplantation.
Storb R; Sandmaier BM
Haematologica; 2016 May; 101(5):521-30. PubMed ID: 27132278
[TBL] [Abstract][Full Text] [Related]
10. Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Willems E; Humblet-Baron S; Dengis O; Seidel L; Beguin Y; Baron F
Bone Marrow Transplant; 2010 Sep; 45(9):1442-8. PubMed ID: 20062090
[TBL] [Abstract][Full Text] [Related]
11. Update on non-myeloablative stem cell transplantation for hematologic malignancies.
Giralt S
Int J Hematol; 2002 Aug; 76 Suppl 1():368-75. PubMed ID: 12430884
[TBL] [Abstract][Full Text] [Related]
12. Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia.
Carella AM; Giralt S; Slavin S
Haematologica; 2000 Mar; 85(3):304-13. PubMed ID: 10702821
[TBL] [Abstract][Full Text] [Related]
13. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation.
Champlin R; Khouri I; Anderlini P; Gajewski J; Kornblau S; Molldrem J; Shimoni A; Ueno N; Giralt S
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S13-22. PubMed ID: 11436116
[TBL] [Abstract][Full Text] [Related]
14. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
Foss FM
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
[TBL] [Abstract][Full Text] [Related]
15. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
Resnick IB; Shapira MY; Slavin S
Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
[TBL] [Abstract][Full Text] [Related]
16. Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens.
Banna GL; Aversa S; Sileni VC; Favaretto A; Ghiotto C; Monfardini S
Crit Rev Oncol Hematol; 2004 Sep; 51(3):171-89. PubMed ID: 15331077
[TBL] [Abstract][Full Text] [Related]
17. Minitransplants: allogeneic stem cell transplantation with reduced toxicity.
Beguin Y; Baron F
Acta Clin Belg; 2003; 58(1):37-45. PubMed ID: 12723260
[TBL] [Abstract][Full Text] [Related]
18. Can reduced-intensity allogeneic transplantation cure older adults with AML?
Storb R
Best Pract Res Clin Haematol; 2007 Mar; 20(1):85-90. PubMed ID: 17336258
[TBL] [Abstract][Full Text] [Related]
19. Nonmyeloablative allogeneic hematopoietic stem cell transplantation.
Baron F; Beguin Y
J Hematother Stem Cell Res; 2002 Apr; 11(2):243-63. PubMed ID: 11983097
[TBL] [Abstract][Full Text] [Related]
20. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
